ArticleFrontiers in pharmacology2013
Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved.
Article in Frontiers in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2016Pooled it
- Do withdrawal symptoms predict depression relapse after antidepressant cessation?European archives of psychiatry and clinical neuroscience · 2026Trial
- Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.The international journal of neuropsychopharmacology · 2021Trial
- Trial
- Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal-hippocampal circuitry.Molecular psychiatry · 2026Article
- Concomitant use of antidepressants and classic psychedelics: A scoping review.Journal of psychopharmacology (Oxford, England) · 2025Article
- A behavioral activation mobile application for depression among Korean young adults: a pilot study of multi-modal app usage patterns and clinical outcomes.Frontiers in psychiatry · 2025Article
- Effective Pain Management of Postherpetic Neuralgia Using a Combination of Analgesics and Conservative Measures.Cureus · 2024Article
- Rebound activation of 5-HT neurons following SSRI discontinuation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.Psychopharmacology · 2024Article
- Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.Molecular psychiatry · 2024Review
- Mechanisms of SSRI Therapy and Discontinuation.Current topics in behavioral neurosciences · 2024Review
- Pharmacotherapy for Depression and Anxiety in the Primary Care Setting.The journal for nurse practitioners : JNP · 2023Article
- Review
- Home-administered transcranial direct current stimulation is a feasible intervention for depression: an observational cohort study.Frontiers in psychiatry · 2023Article
- Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice.Journal of psychopharmacology (Oxford, England) · 2022Article
- Case report: Chronological symptom profile after cessation of overdose zolpidem in a patient with comorbid bipolar disorder-from anxiety, craving, paresthesia and influenza-like symptoms to seizures and hallucinations.Frontiers in psychiatry · 2022Article
- Critiquing the Critique: Resisting Commonplace Criticisms of Antidepressants in Online Platforms.Qualitative health research · 2021Article
- Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery.Hepatology (Baltimore, Md.) · 2021Article
- What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications.Therapeutic advances in psychopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides demonstrated efficacy, selective serotonin reuptake inhibitors (SSRIs) hold other advantages over earlier antidepressants such as greater tolerability and a wider range of clinical applications. However, there is a growing body of clinical evidence which suggests that SSRIs could, in some cases, be associated with a withdrawal reaction upon cessation of regular use. In addition to sensory and gastrointestinal-related symptoms, the somatic symptoms of the SSRI discontinuation syndrome include dizziness, lethargy, and sleep disturbances. Psychological symptoms have also been documented, usually developing within 1-7 days following SSRI discontinuation. The characteristics of the discontinuation syndrome have been linked to the half-life of a given SSRI, with a greater number of reports emerging from paroxetine compared to other SSRIs. However, many aspects of the neurobiology of the SSRI discontinuation syndrome (or SSRI withdrawal syndrome) remain unresolved. Following a comprehensive overview of the clinical evidence, we will discuss the underlying pathophysiology of the SSRI discontinuation syndrome and comment on the use of animal models to better understand this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.